Cholecystokinin and Pancreatic Cancer in Hamsters
Author Information
Author(s): A.G. Howatson, D.C. Carter
Primary Institution: University Department of Surgery, Royal Infirmary, Glasgow, Scotland, UK
Hypothesis
Does cholecystokinin enhance pancreatic carcinogenesis in the hamster-nitrosamine model?
Conclusion
Cholecystokinin acts as a co-carcinogen, reducing the latency period and increasing the induction rate of pancreatic tumors.
Supporting Evidence
- Exogenous cholecystokinin increased pancreatic wet weight significantly.
- CCK treatment resulted in earlier and more frequent ductal lesions in hamsters.
- Histological assessments showed a significant increase in duct carcinoma-in-situ in CCK treated groups.
Takeaway
This study found that a hormone called cholecystokinin can make hamsters more likely to get pancreatic cancer when they are exposed to certain chemicals.
Methodology
The study involved administering cholecystokinin and a carcinogen to groups of hamsters and assessing pancreatic changes over time.
Limitations
Some animals died from unrelated infections, which may have affected the results.
Participant Demographics
10-week-old male Syrian hamsters
Statistical Information
P-Value
p<0.02
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website